<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre, +50

New England Journal of Medicine

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert, +25

The Lancet Oncology

MedicineMelanomaImmunologyBrafv600k Mutation-positive MelanomaCancer Treatment +7

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

Kerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, +26

Journal of Clinical Oncology

MedicineReceptor Tyrosine Kinase-Mutant MelanomaPharmacologyMelanoma +12

Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec, +9

Journal of Clinical Oncology

Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

Mario E. Lacouture, Madeleine Duvic, Axel Hauschild, +16

The Oncologist

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Fei Su, William D. Bradley, Qiongqing Wang, +18

Cancer Research

Cancer BiologyTumor BiologySignaling PathwayReceptor Tyrosine KinaseKras Protein +14

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Andrea Ardizzoni, Sérgio Jobim Azevedo, Belén Rubio‐Viqueira, +11

Journal for ImmunoTherapy of Cancer

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

Jennifer Moriatis Wolf, Åslaug Helland, In‐Jae Oh, +12

ESMO Open

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts).

Grant A. McArthur, Antoni Ribas, Paul B. Chapman, +11

Journal of Clinical Oncology

PathologyImmunotherapeuticsMelanoma Extension PhaseTumor BiologyOncology +15

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in <i>BRAF^V600E</i>melanoma.

Jeffrey A. Sosman, Anna C. Pavlick, Lynn M. Schuchter, +17

Journal of Clinical Oncology

ImmunologyCancer BiologyTumor BiologyDrug ResistanceMolecular Pharmacology +20